002773 康弘药业
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)6.10112.95614.47714.20913.804
总资产报酬率 ROA (%)5.68812.07513.33112.85812.219
投入资产回报率 ROIC (%)6.08512.91714.40214.05713.516

边际利润分析
销售毛利率 (%)88.49789.84989.52488.92288.550
营业利润率 (%)30.98830.04031.02331.86629.960
息税前利润/营业总收入 (%)28.98528.42528.97629.85729.075
净利润/营业总收入 (%)25.46624.98326.43426.05525.547

收益指标分析
经营活动净收益/利润总额(%)99.41096.33395.56393.23188.628
价值变动净收益/利润总额(%)1.5042.7133.4173.5823.694
营业外收支净额/利润总额(%)-2.256-1.567-2.129-2.2001.449

偿债能力分析
流动比率 (X)10.03411.7749.6018.1076.097
速动比率 (X)9.46511.0979.0117.4905.620
资产负债率 (%)7.6296.5047.4408.41510.541
带息债务/全部投入资本 (%)-0.195-0.246-0.067-0.149-0.179
股东权益/带息债务 (%)-51,194.673-40,488.549-148,405.851-66,839.353-55,068.346
股东权益/负债合计 (%)1,215.1961,441.2081,244.9411,087.270848.043
利息保障倍数 (X)-21.971-24.698-20.696-22.569-21.924

营运能力分析
应收账款周转天数 (天)19.66014.39113.65914.10117.676
存货周转天数 (天)291.629307.043305.027301.598290.659